RxDoctor Payments Data

Kellen Jex, MD

Gastroenterology · Ferriday, LANPI 1952698532

Payments from drug & device makers

$9,678in general payments, 2019–2025

Across 284 payments — averaging $34.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$5K
  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$853
  • Boston Scientific$269
  • Takeda Pharmaceuticals U.S.A., Inc.$210
  • Aimmune Therapeutics, Inc.$205
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$4,94551%
  • Food & beverage$4,73349%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,678 in reported general payments places this provider in the 70th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$262,198
Medicare patients
782
Services billed
3,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab25$688,183
Humira(Cf) PenAdalimumab28$309,649
CreonLipase/Protease/Amylase64$221,471
ZenpepLipase/Protease/Amylase45$179,355
LinzessLinaclotide75$61,494
XifaxanRifaximin11$35,141
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates368$25,201
Pantoprazole Sodium1,209$15,635
TrulancePlecanatide20$13,086
VoqueznaVonoprazan Fumarate16$10,870
Dexlansoprazole DrDexlansoprazole33$8,771
ClenpiqSod Picosulf/Mag Ox/Citric Ac39$6,632
Colestipol Hcl45$4,307
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C30$4,224
Ursodiol21$2,363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$122$688,18325 claims
AbbVieCreon, Linzess$1,841$282,965139 claims
Aimmune Therapeutics, Inc.Zenpep$205$179,35545 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu$853$52,45161 claims
Phathom Pharmaceuticals, Inc.Voquezna$5,208$10,87016 claims
Braintree Laboratories, Inc.Sutab$26$1,74411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 254 gastroenterology providers in Louisiana.

Other gastroenterology in Ferriday

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →